Skip to main content
Premium Trial:

Request an Annual Quote

HCS Firm Cellumen Snags Series A Funding

NEW YORK, June 20 (GenomeWeb News) - PA Early Stage Partners, a family of venture funds based in Wayne, Penn., said today that it has made a Series A investment in high-content screening firm Cellumen.


Cellumen, based in Pittsburgh, measures proteins and RNA in cells using multiple high-content screening platforms along with several proprietary reagents. It was founded by Lansing Taylor, who also founded the high-content screening tool provider Cellomics.


The amount of the investment was not provided.


For further details on Cellumen's business model and strategy following the financing, see the June 13 issue of Cell-Based Assay News, a GenomeWeb News sister publication.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.